Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cell-type-specific APOE4 cascade across the Alzheimer's disease continuum.

Created on 17 Sep 2026

Authors

David Shostak, Zherui Liang, Yadong Huang

Published in

Neuron. Volume 114. Issue 16. Pages 2929-2956. Aug 19, 2026. Epub May 14, 2026.

Abstract

Apolipoprotein E4 (APOE4) is the leading genetic risk factor and an increasingly recognized causal contributor to Alzheimer's disease (AD). AD progresses along a temporal, pathological, and clinical continuum spanning preclinical, prodromal, and dementia stages. Across this continuum, APOE4 exerts detrimental effects at distinct times and in different cell types, underscoring the need for a model defining not only how but also when and in which cells these effects occur. In this review, we synthesize current findings and propose a temporal model linking cell-type-specific APOE4 expression to AD progression. In this model, age-associated stress upregulates neuronal APOE4 expression, leading to early neuronal deficits characteristic of preclinical AD. Neuronal APOE4-induced damage subsequently triggers a harmful glial response that, alongside glial APOE4, amplifies neurodegeneration and accelerates the onset of prodromal and dementia AD. This model highlights the temporal and cellular dynamics of APOE4 effects and suggests stage- and cell-type-specific therapeutics targeting APOE4-driven mechanisms across the AD continuum.

PMID:
42140183
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement